{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:37:46Z","timestamp":1773283066633,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:00:00Z","timestamp":1311638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s15010-011-0161-1","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T05:59:59Z","timestamp":1311573599000},"page":"515-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy"],"prefix":"10.1007","volume":"39","author":[{"given":"R.","family":"Guner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Hasanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Keske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. K.","family":"Kalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Tasyaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"161_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijantimicag.2009.10.024","volume":"35","author":"NC Gordon","year":"2010","unstructured":"Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35:219\u201326.","journal-title":"Int J Antimicrob Agents"},{"key":"161_CR2","first-page":"236","volume":"17","author":"R Ricciardi","year":"2009","unstructured":"Ricciardi R, Ricciardi AM, Danzi G. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. Infez Med. 2009;17:236\u20139.","journal-title":"Infez Med"},{"key":"161_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3201\/eid1301.060716","volume":"13","author":"RH Sunenshine","year":"2007","unstructured":"Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97\u2013103.","journal-title":"Emerg Infect Dis"},{"key":"161_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10096-008-0473-y","volume":"27","author":"DW Wareham","year":"2008","unstructured":"Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, Millar M. Bloodstream infection due to Acinetobacter spp.: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008;27:607\u201312.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"161_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/jac\/dki248","volume":"56","author":"GA Pankey","year":"2005","unstructured":"Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56:470\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"161_CR6","unstructured":"TYGACIL product information. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021821s021lbl.pdf. Accessed 16 July 2010."},{"key":"161_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","volume":"16","author":"JS Garner","year":"1988","unstructured":"Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128\u201340.","journal-title":"Am J Infect Control"},{"key":"161_CR8","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1056\/NEJMe068231","volume":"355","author":"MH Kollef","year":"2006","unstructured":"Kollef MH. Diagnosis of ventilator-associated pneumonia. N Engl J Med. 2006;355:2691\u20133.","journal-title":"N Engl J Med"},{"key":"161_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1086\/646436","volume":"13","author":"TC Horan","year":"1992","unstructured":"Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606\u20138.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"161_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkn555","volume":"63","author":"NC Gordon","year":"2009","unstructured":"Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother. 2009;63:775\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"161_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jinf.2009.02.009","volume":"58","author":"G Poulakou","year":"2009","unstructured":"Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, Nicolaou C, Yphantis D, Antoniadou A, Trikka-Graphakos E, Roussou Z, Clouva P, Maguina N, Kanellakopoulou K, Armaganidis A, Giamarellou H. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect. 2009;58:273\u201384.","journal-title":"J Infect"},{"key":"161_CR12","volume-title":"Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Wayne, PA: CLSI; 2008."},{"key":"161_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1128\/JCM.01588-06","volume":"45","author":"RN Jones","year":"2007","unstructured":"Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007;45:227\u201330.","journal-title":"J Clin Microbiol"},{"key":"161_CR14","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1097\/00003246-199909000-00015","volume":"27","author":"JL Garc\u00eda-Garmendia","year":"1999","unstructured":"Garc\u00eda-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jim\u00e9nez-Jim\u00e9nez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999;27:1794\u20139.","journal-title":"Crit Care Med"},{"key":"161_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1179\/joc.2010.22.2.110","volume":"22","author":"G Metan","year":"2010","unstructured":"Metan G, Alp E, Yildiz O, Percin D, Aygen B, Sumerkan B. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J Chemother. 2010;22:110\u20134.","journal-title":"J Chemother"},{"key":"161_CR16","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/jac\/dkn249","volume":"62","author":"K Vasilev","year":"2008","unstructured":"Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62:i29\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"161_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10096-010-0942-y","volume":"29","author":"E Garc\u00eda-Cabrera","year":"2010","unstructured":"Garc\u00eda-Cabrera E, Jim\u00e9nez-Mej\u00edas ME, Gil Navarro MV, G\u00f3mez-G\u00f3mez MJ, Ortiz-Leyba C, Cordero E, Pach\u00f3n J; Hospitale Universitarios Virgen del Roc\u00edo. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis. 2010;29:867\u201371.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"161_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/jac\/dkl499","volume":"59","author":"KT Kwon","year":"2007","unstructured":"Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007;59:525\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"161_CR19","first-page":"127","volume":"38","author":"HP Chen","year":"2005","unstructured":"Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY. Predictors of mortality in Acinetobacter baumannii bacteraemia. J Microbiol Immunol Infect. 2005;38:127\u201336.","journal-title":"J Microbiol Immunol Infect"},{"key":"161_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/jac\/dkl130","volume":"57","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother. 2006;57:1251\u20134.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-011-0161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-011-0161-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-011-0161-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-011-0161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:30:30Z","timestamp":1744169430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-011-0161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1007\/s15010-011-0161-1","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]},"assertion":[{"value":"9 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}